BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23658847)

  • 21. Co-infection of HIV in patients with Buruli ulcer disease in Central Ghana.
    Amoako YA; Loglo AD; Frimpong M; Agbavor B; Abass MK; Amofa G; Ofori E; Ampadu E; Asiedu K; Stienstra Y; Wansbrough-Jones M; van der Werf T; Phillips RO
    BMC Infect Dis; 2021 Apr; 21(1):331. PubMed ID: 33832460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycobacterium ulcerans disease in the middle belt of Ghana: An eight-year review from six endemic districts.
    Adu EJ; Ampadu E
    Int J Mycobacteriol; 2015 Jun; 4(2):138-42. PubMed ID: 26972882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.
    Sarfo FS; Phillips R; Asiedu K; Ampadu E; Bobi N; Adentwe E; Lartey A; Tetteh I; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3678-85. PubMed ID: 20566765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
    Converse PJ; Nuermberger EL; Almeida DV; Grosset JH
    Future Microbiol; 2011 Oct; 6(10):1185-98. PubMed ID: 22004037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection.
    Martins TG; Gama JB; Fraga AG; Saraiva M; Silva MT; Castro AG; Pedrosa J
    PLoS One; 2012; 7(2):e32740. PubMed ID: 22393444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges associated with the treatment of Buruli ulcer.
    Aboagye SY; Kpeli G; Tuffour J; Yeboah-Manu D
    J Leukoc Biol; 2019 Feb; 105(2):233-242. PubMed ID: 30168876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.
    Etuaful S; Carbonnelle B; Grosset J; Lucas S; Horsfield C; Phillips R; Evans M; Ofori-Adjei D; Klustse E; Owusu-Boateng J; Amedofu GK; Awuah P; Ampadu E; Amofah G; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3182-6. PubMed ID: 16048922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic diversity of Staphylococcus aureus in Buruli ulcer.
    Amissah NA; Glasner C; Ablordey A; Tetteh CS; Kotey NK; Prah I; van der Werf TS; Rossen JW; van Dijl JM; Stienstra Y
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003421. PubMed ID: 25658641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease.
    Sarfo FS; Converse PJ; Almeida DV; Zhang J; Robinson C; Wansbrough-Jones M; Grosset JH
    PLoS Negl Trop Dis; 2013; 7(3):e2101. PubMed ID: 23516649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploration of a standard treatment for Buruli ulcer through a comprehensive analysis of all cases diagnosed in Japan.
    Sugawara M; Ishii N; Nakanaga K; Suzuki K; Umebayashi Y; Makigami K; Aihara M
    J Dermatol; 2015 Jun; 42(6):588-95. PubMed ID: 25809502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease.
    Sarfo FS; Phillips RO; Zhang J; Abass MK; Abotsi J; Amoako YA; Adu-Sarkodie Y; Robinson C; Wansbrough-Jones MH
    BMC Infect Dis; 2014 Apr; 14():202. PubMed ID: 24731247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Buruli ulcer disease in Republic of the Congo.
    Marion E; Obvala D; Babonneau J; Kempf M; Asiedu KB; Marsollier L
    Emerg Infect Dis; 2014 Jun; 20(6):1070-2. PubMed ID: 24857328
    [No Abstract]   [Full Text] [Related]  

  • 33. Buruli Ulcer: Review of a Neglected Skin Mycobacterial Disease.
    Guarner J
    J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29343539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buruli ulcer. A disabling infection.
    Prescrire Int; 2010 Nov; 19(110):261-2. PubMed ID: 21284361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study.
    O'Brien DP; McDonald A; Callan P; Robson M; Friedman ND; Hughes A; Holten I; Walton A; Athan E
    PLoS Negl Trop Dis; 2012 Jan; 6(1):e1473. PubMed ID: 22272368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary bacterial isolates from previously untreated Buruli ulcer lesions and their antibiotic susceptibility patterns in Southern Nigeria.
    Anyim MC; Meka AO; Chukwu JN; Nwafor CC; Oshi DC; Madichie NO; Ekeke N; Alphonsus C; Mbah O; Nwaekpe C; Njoku M; Fakiyesi D; Ulodiaku V; Ejiofor I; Bisiriyu AH; Ukwaja KN
    Rev Soc Bras Med Trop; 2016; 49(6):746-751. PubMed ID: 28001222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin.
    Johnson RC; Sáez-López E; Anagonou ES; Kpoton GG; Ayelo AG; Gnimavo RS; Mignanwande FZ; Houezo JG; Sopoh GE; Addo J; Orford L; Vlasakakis G; Biswas N; Calderon F; Della Pasqua O; Gine-March A; Herrador Z; Mendoza-Losana A; Díez G; Cruz I; Ramón-García S
    Trials; 2022 Jul; 23(1):559. PubMed ID: 35804454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.
    Zhang T; Li SY; Converse PJ; Almeida DV; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2011 Jan; 55(1):56-61. PubMed ID: 21078940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Streptomycin injections for the treatment of Mycobacterium ulcerans (Buruli ulcer) in a rural health zone in the Democratic Republic of the Congo].
    Kibadi K
    Sante; 2007; 17(3):173-6. PubMed ID: 18180219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans.
    Sarfo FS; Phillips RO; Ampadu E; Sarpong F; Adentwe E; Wansbrough-Jones M
    Clin Vaccine Immunol; 2009 Jan; 16(1):61-5. PubMed ID: 19005025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.